tetano
Editor, Senior Moderator
Nature
. 2020 Aug 5.
doi: 10.1038/s41586-020-2622-0. Online ahead of print.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S Corbett[SUP] 1 [/SUP], Darin K Edwards[SUP] 2 [/SUP], Sarah R Leist[SUP] 3 [/SUP], Olubukola M Abiona[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], Rebecca A Gillespie[SUP] 1 [/SUP], Sunny Himansu[SUP] 2 [/SUP], Alexandra Sch?fer[SUP] 3 [/SUP], Cynthia T Ziwawo[SUP] 1 [/SUP], Anthony T DiPiazza[SUP] 1 [/SUP], Kenneth H Dinnon[SUP] 3 [/SUP], Sayda M Elbashir[SUP] 2 [/SUP], Christine A Shaw[SUP] 2 [/SUP], Angela Woods[SUP] 2 [/SUP], Ethan J Fritch[SUP] 4 [/SUP], David R Martinez[SUP] 3 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Geoffrey B Hutchinson[SUP] 1 [/SUP], Kai Wu[SUP] 2 [/SUP], Carole Henry[SUP] 2 [/SUP], Kapil Bahi[SUP] 2 [/SUP], Dario Garcia-Dominguez[SUP] 2 [/SUP], LingZhi Ma[SUP] 2 [/SUP], Isabella Renzi[SUP] 2 [/SUP], Wing-Pui Kong[SUP] 1 [/SUP], Stephen D Schmidt[SUP] 1 [/SUP], Lingshu Wang[SUP] 1 [/SUP], Yi Zhang[SUP] 1 [/SUP], Emily Phung[SUP] 1 6 [/SUP], Lauren A Chang[SUP] 1 [/SUP], Rebecca J Loomis[SUP] 1 [/SUP], Nedim Emil Altaras[SUP] 2 [/SUP], Elisabeth Narayanan[SUP] 2 [/SUP], Mihir Metkar[SUP] 2 [/SUP], Vlad Presnyak[SUP] 2 [/SUP], Cuiping Liu[SUP] 1 [/SUP], Mark K Louder[SUP] 1 [/SUP], Wei Shi[SUP] 1 [/SUP], Kwanyee Leung[SUP] 1 [/SUP], Eun Sung Yang[SUP] 1 [/SUP], Ande West[SUP] 3 [/SUP], Kendra L Gully[SUP] 3 [/SUP], Laura J Stevens[SUP] 7 [/SUP], Nianshuang Wang[SUP] 8 [/SUP], Daniel Wrapp[SUP] 8 [/SUP], Nicole A Doria-Rose[SUP] 1 [/SUP], Guillaume Stewart-Jones[SUP] 2 [/SUP], Hamilton Bennett[SUP] 2 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Martha C Nason[SUP] 9 [/SUP], Tracy J Ruckwardt[SUP] 1 [/SUP], Jason S McLellan[SUP] 8 [/SUP], Mark R Denison[SUP] 7 [/SUP], James D Chappell[SUP] 7 [/SUP], Ian N Moore[SUP] 5 [/SUP], Kaitlyn M Morabito[SUP] 1 [/SUP], John R Mascola[SUP] 1 [/SUP], Ralph S Baric[SUP] 3 4 [/SUP], Andrea Carfi[SUP] 10 [/SUP], Barney S Graham[SUP] 11 [/SUP]
Affiliations
Abstract
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved the expression and immunogenicity of betacoronavirus spike proteins[SUP]1[/SUP]. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant[SUP]2[/SUP] SARS-CoV-2 and CD8 T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation.
. 2020 Aug 5.
doi: 10.1038/s41586-020-2622-0. Online ahead of print.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S Corbett[SUP] 1 [/SUP], Darin K Edwards[SUP] 2 [/SUP], Sarah R Leist[SUP] 3 [/SUP], Olubukola M Abiona[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], Rebecca A Gillespie[SUP] 1 [/SUP], Sunny Himansu[SUP] 2 [/SUP], Alexandra Sch?fer[SUP] 3 [/SUP], Cynthia T Ziwawo[SUP] 1 [/SUP], Anthony T DiPiazza[SUP] 1 [/SUP], Kenneth H Dinnon[SUP] 3 [/SUP], Sayda M Elbashir[SUP] 2 [/SUP], Christine A Shaw[SUP] 2 [/SUP], Angela Woods[SUP] 2 [/SUP], Ethan J Fritch[SUP] 4 [/SUP], David R Martinez[SUP] 3 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Geoffrey B Hutchinson[SUP] 1 [/SUP], Kai Wu[SUP] 2 [/SUP], Carole Henry[SUP] 2 [/SUP], Kapil Bahi[SUP] 2 [/SUP], Dario Garcia-Dominguez[SUP] 2 [/SUP], LingZhi Ma[SUP] 2 [/SUP], Isabella Renzi[SUP] 2 [/SUP], Wing-Pui Kong[SUP] 1 [/SUP], Stephen D Schmidt[SUP] 1 [/SUP], Lingshu Wang[SUP] 1 [/SUP], Yi Zhang[SUP] 1 [/SUP], Emily Phung[SUP] 1 6 [/SUP], Lauren A Chang[SUP] 1 [/SUP], Rebecca J Loomis[SUP] 1 [/SUP], Nedim Emil Altaras[SUP] 2 [/SUP], Elisabeth Narayanan[SUP] 2 [/SUP], Mihir Metkar[SUP] 2 [/SUP], Vlad Presnyak[SUP] 2 [/SUP], Cuiping Liu[SUP] 1 [/SUP], Mark K Louder[SUP] 1 [/SUP], Wei Shi[SUP] 1 [/SUP], Kwanyee Leung[SUP] 1 [/SUP], Eun Sung Yang[SUP] 1 [/SUP], Ande West[SUP] 3 [/SUP], Kendra L Gully[SUP] 3 [/SUP], Laura J Stevens[SUP] 7 [/SUP], Nianshuang Wang[SUP] 8 [/SUP], Daniel Wrapp[SUP] 8 [/SUP], Nicole A Doria-Rose[SUP] 1 [/SUP], Guillaume Stewart-Jones[SUP] 2 [/SUP], Hamilton Bennett[SUP] 2 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Martha C Nason[SUP] 9 [/SUP], Tracy J Ruckwardt[SUP] 1 [/SUP], Jason S McLellan[SUP] 8 [/SUP], Mark R Denison[SUP] 7 [/SUP], James D Chappell[SUP] 7 [/SUP], Ian N Moore[SUP] 5 [/SUP], Kaitlyn M Morabito[SUP] 1 [/SUP], John R Mascola[SUP] 1 [/SUP], Ralph S Baric[SUP] 3 4 [/SUP], Andrea Carfi[SUP] 10 [/SUP], Barney S Graham[SUP] 11 [/SUP]
Affiliations
- PMID: 32756549
- DOI: 10.1038/s41586-020-2622-0
Abstract
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved the expression and immunogenicity of betacoronavirus spike proteins[SUP]1[/SUP]. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant[SUP]2[/SUP] SARS-CoV-2 and CD8 T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation.